<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620204</url>
  </required_header>
  <id_info>
    <org_study_id>2008-01-018</org_study_id>
    <nct_id>NCT00620204</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Atorvastatin to Treat Variant Angina</brief_title>
  <acronym>ESAVA</acronym>
  <official_title>Efficacy Study of Atorvastatin to Treat Variant Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate effect of statin treatment for vasospastic angina.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vasospastic angina is presented by myocardial ischemia with spasm of coronary artery
      accompanying chest pain or discomfort. The precise mechanisms have not been established, but
      a reduction in NO (nitric oxide) production, an imbalance between endothelium-derived
      relaxing and contracting factors,or an injury of endothelium have been suggested.

      Impaired FMD(flow mediated endothelium-dependent vasodilation) in the brachial artery was
      demonstrated in vasospastic angina,and improvement of endothelial dysfunction with treatment
      of statin is documented in several studies.

      So, we expect that statin treatment for vasospastic angina provide additional therapeutic
      effects via improvement of endothelial dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ergonovine provocation test 24hrs later after admission</measure>
    <time_frame>1 year later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chest pain with EKG change during admission for 24hrs at 12mo. later (All medications are withheld for 48hrs. before admission)</measure>
    <time_frame>1year later</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Angina Pectoris, Variant</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 40mg qd for 1 year</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lipitor®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vasospastic angina or spontaneous spasm during coronary angiography (Vasospastic
             angina is defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade 0-2 noted
             in intracoronary ergonovine provocation test and development of chest pain or EKG
             change; Spontaneous spasm is defined as TIMI flow grade 0-2 of coronary artery without
             ergonovine injection)

          -  Normal or insignificant lesion (diameter stenosis &lt;50%) on coronary angiography

        Exclusion Criteria:

          -  Elevated liver enzyme: serum aspartate aminotransferase or alanine aminotransferase
             concentrations more than 3 times the upper limit of normal

          -  Significant lesion( diameter stenosis ≥50%) documented in coronary angiography

          -  Pregnancy

          -  Prior percutaneous coronary intervention or coronary artery bypass surgery

          -  Previous statin use

          -  Impaired renal function with serum creatinine ≥ 2.0 mg/dl

          -  Severe left ventricular dysfunction ( LVEF ≤ 30% on echocardiography)

          -  Myopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-chul Gwon, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-chul Gwon, MD,PhD</last_name>
    <phone>82-2-3410-3418</phone>
    <email>hcgwon@smc.samsung.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2008</study_first_submitted>
  <study_first_submitted_qc>February 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>HC Gwon, MD,PhD / Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>Angina Pectoris, Variant</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina Pectoris, Variant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

